Thursday, August 11, 2022 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

LOS ANGELES - Obagi pharmaceuticals is selling itself too cheaply to Valeant Pharmaceuticals, for $19.75 a share or $360 million, shareholders claim in Superior Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.